Detecting GPC1-positive circulating exosomes (crExos) is a reliable way to identify early-stage pancreatic cancer, and these GPC1-positive crExos are even more effective as a prognostic marker compared to the current serum biomarker CA 19-9 72. Here, GPC1 is linked to familial pancreatic carcinoma.